Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 5/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25066041 | 0.88 | PRKCI (0.52) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29999204 | 0.88 | PRKCI (0.52) | ESR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1895629 | 0.88 | PDE5A (0.52) | PDE5AAPPESR1CDK1PDE4A | |
| SCHEMBL1896587 | 0.82 | ESR1 (0.49) | PDE5AAPPESR1CDK1PDE4A | |
| SCHEMBL23518886 | 0.82 | SMN1; SMN2 (0.51) | PDE5AESR1PDE4APDE4BPDE4C | |
| SCHEMBL1897657 | 0.81 | ESR1 (0.48) | PDE5AAPPESR1CDK1PDE4A | |
| Hydrochloric Acid SCHEMBL31220566 | 0.81 | SMN1; SMN2 (0.50) | PDE5AESR1PDE4APDE4BPDE4C | |
| SCHEMBL7677294 | 0.80 | PRKCI (0.44) | ESR1PDE4BPRKCIMAPT | |
| SCHEMBL23498575 | 0.80 | SMN1; SMN2 (0.49) | ESR1MAPT | |
| SCHEMBL7677299 | 0.79 | PRKCI (0.38) | PDE5AAPPESR1CDK1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | PDE5A 1487/4885APP 4396/4885ESR1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.